There are reports on the largest biopharma M&A deals, with some outlets focusing on specific years such as 2019. The biopharma M&A market appears to be active, with some sources suggesting it is on track for a strong year, driven by factors like patent expiries. The value and number of biopharma M&A deals have fluctuated over the years, with some sources providing data on historical trends and others discussing the current deal landscape.